Long-Term Response with Eribulin Mesylate in a Breast Cancer Patient: A Case Report.

Despite the wide pharmacological armamentarium available for the treatment of metastatic breast cancer (MBC), long-lasting control of disease is challenging, especially in heavily pretreated patients. In this case report, we documented a long-lasting complete response (CR) with eribulin in a relatively young woman with MBC and bone metastasis, who did not benefit from prior chemotherapy regimens. Besides CR, the patient was able to maintain an excellent performance status and was free from the severe pain experienced before the initiation of eribulin. Noteworthy, eribulin treatment was very well tolerated, with only a mild alopecia being reported; response was maintained also after a temporary dose interruption and a therapeutic holiday due to non-treatment-related increase in liver enzymes and steatosis.